A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors
Sponsor: |
GlaxoSmithKline |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR8356 |
U.S. Govt. ID: |
NCT02723955 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
GSK3359609 is a drug that is a type of antibody. It is a kind of immunotherapy that targets the ICOS (anti-Inducible T cell Co-Stimulator) protein present on specific immune cells. ICOS is a cell receptor that enhances the immune response to foreign bodies, and which is expected to help your immune system find and fight cancer cells. It will also be called the ICOS study drug. The ICOS study drug has only been given to people who participated in this study. The ICOS study drug is not yet approved for doctors to treat patients with cancer. The study is being done to find out what effects, good or bad, it has on people with certain types of cancer. Cancer types include: bladder cancer, colon and rectal cancer, esophageal cancer, gynecologic cancers (cervical cancer), head and neck/oral cancers, lung cancer, melanoma, and prostate cancer.
This study is closed
Investigator
Brian Henick, MD
Are you 18 years or older? |
Yes |
No |
Is your disease locally advanced/metastatic or has it recurred/not responded to treatment? |
Yes |
No |
Has your disease recurred following standard therapy or are there no current standard therapies available for you? |
Yes |
No |
Are you willing to undergo a biopsy before you start treatment and while you are on treatment? |
Yes |
No |